AcouSort AB (ACOU) - Net Assets
Based on the latest financial reports, AcouSort AB (ACOU) has net assets worth Skr13.74 Million SEK (≈ $1.48 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr26.52 Million ≈ $2.85 Million USD) and total liabilities (Skr12.79 Million ≈ $1.38 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AcouSort AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr13.74 Million |
| % of Total Assets | 51.79% |
| Annual Growth Rate | 41.67% |
| 5-Year Change | -50.64% |
| 10-Year Change | 63.75% |
| Growth Volatility | 3461.87 |
AcouSort AB - Net Assets Trend (2013–2025)
This chart illustrates how AcouSort AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of AcouSort AB.
Annual Net Assets for AcouSort AB (2013–2025)
The table below shows the annual net assets of AcouSort AB from 2013 to 2025. Also explore ACOU net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr16.30 Million ≈ $1.75 Million |
+92.61% |
| 2024-12-31 | Skr8.46 Million ≈ $910.75K |
-64.93% |
| 2023-12-31 | Skr24.14 Million ≈ $2.60 Million |
+19.99% |
| 2022-12-31 | Skr20.11 Million ≈ $2.16 Million |
-39.09% |
| 2021-12-31 | Skr33.02 Million ≈ $3.55 Million |
+244.27% |
| 2020-12-31 | Skr9.59 Million ≈ $1.03 Million |
+61.97% |
| 2019-12-31 | Skr5.92 Million ≈ $637.30K |
-61.99% |
| 2018-12-31 | Skr15.58 Million ≈ $1.68 Million |
+301.21% |
| 2017-12-31 | Skr3.88 Million ≈ $417.87K |
-60.99% |
| 2016-12-31 | Skr9.96 Million ≈ $1.07 Million |
+12560.56% |
| 2015-12-31 | Skr78.63K ≈ $8.46K |
-79.11% |
| 2014-12-31 | Skr376.48K ≈ $40.52K |
+50.91% |
| 2013-12-31 | Skr249.47K ≈ $26.85K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AcouSort AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51916.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.12 Million | 12.98% |
| Other Comprehensive Income | Skr72.00K | 0.44% |
| Other Components | Skr117.47 Million | 720.64% |
| Total Equity | Skr16.30 Million | 100.00% |
AcouSort AB Competitors by Market Cap
The table below lists competitors of AcouSort AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Corella Resources Ltd
AU:CR9
|
$6.79 Million |
|
IL&FS Transportation Networks Limited
NSE:IL&FSTRANS
|
$6.79 Million |
|
TNF Pharmaceuticals, Inc.
NASDAQ:TNFA
|
$6.80 Million |
|
DGB Group NV
AS:DGB
|
$6.80 Million |
|
Micro Digital Co. Ltd
KQ:305090
|
$6.78 Million |
|
PLAYWITH Inc
KQ:023770
|
$6.78 Million |
|
ECS Botanics Holdings Ltd
AU:ECS
|
$6.78 Million |
|
Openn Negotiation Ltd
AU:OPN
|
$6.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AcouSort AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,463,000 to 16,300,999, a change of 7,837,999 (92.6%).
- Net loss of 12,153,000 reduced equity.
- New share issuances of 25,085,000 increased equity.
- Other comprehensive income increased equity by 117,000.
- Other factors decreased equity by 5,211,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-12.15 Million | -74.55% |
| Share Issuances | Skr25.09 Million | +153.89% |
| Other Comprehensive Income | Skr117.00K | +0.72% |
| Other Changes | Skr-5.21 Million | -31.97% |
| Total Change | Skr- | 92.61% |
Book Value vs Market Value Analysis
This analysis compares AcouSort AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 95.72x to 3.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.03 | Skr2.98 | x |
| 2014-12-31 | Skr0.05 | Skr2.98 | x |
| 2015-12-31 | Skr0.01 | Skr2.98 | x |
| 2016-12-31 | Skr1.24 | Skr2.98 | x |
| 2017-12-31 | Skr0.50 | Skr2.98 | x |
| 2018-12-31 | Skr1.51 | Skr2.98 | x |
| 2019-12-31 | Skr0.57 | Skr2.98 | x |
| 2020-12-31 | Skr0.82 | Skr2.98 | x |
| 2021-12-31 | Skr2.49 | Skr2.98 | x |
| 2022-12-31 | Skr1.52 | Skr2.98 | x |
| 2023-12-31 | Skr1.82 | Skr2.98 | x |
| 2024-12-31 | Skr0.57 | Skr2.98 | x |
| 2025-12-31 | Skr0.86 | Skr2.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AcouSort AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -177.34%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.10x
- Recent ROE (-74.55%) is above the historical average (-96.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -25.14% | -7.53% | 0.34x | 9.67x | Skr-87.67K |
| 2014 | 28.69% | 5.55% | 2.12x | 2.44x | Skr70.36K |
| 2015 | -354.63% | -17.70% | 6.04x | 3.32x | Skr-286.71K |
| 2016 | -8.34% | -30.49% | 0.23x | 1.21x | Skr-1.83 Million |
| 2017 | -156.37% | -244.64% | 0.50x | 1.27x | Skr-6.46 Million |
| 2018 | -57.51% | -834.26% | 0.06x | 1.12x | Skr-10.52 Million |
| 2019 | -163.51% | -521.71% | 0.23x | 1.36x | Skr-10.28 Million |
| 2020 | -85.70% | -166.80% | 0.37x | 1.37x | Skr-9.18 Million |
| 2021 | -37.49% | -411.74% | 0.08x | 1.11x | Skr-15.68 Million |
| 2022 | -65.68% | -266.19% | 0.12x | 2.12x | Skr-15.22 Million |
| 2023 | -70.81% | -161.97% | 0.31x | 1.43x | Skr-19.50 Million |
| 2024 | -178.16% | -318.30% | 0.38x | 1.46x | Skr-15.92 Million |
| 2025 | -74.55% | -177.34% | 0.38x | 1.10x | Skr-13.78 Million |
Industry Comparison
This section compares AcouSort AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $170,698,087
- Average return on equity (ROE) among peers: -107.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AcouSort AB (ACOU) | Skr13.74 Million | -25.14% | 0.93x | $6.79 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $8.55 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $12.40 Million |
| Alzinova AB (ALZ) | $947.42K | -195.83% | 0.18x | $9.77 Million |
| AlzeCure Pharma (ALZCUR) | $60.48 Million | -92.65% | 0.17x | $95.72 Million |
| Annexin Pharmaceuticals AB (ANNX) | $2.71 Million | -51.19% | 0.36x | $9.14 Million |
| Alligator Bioscience AB (ATORX) | $115.24 Million | -124.61% | 0.32x | $2.29 Million |
| BioInvent International AB (BINV) | $55.63 Million | -317.55% | 1.27x | $158.27 Million |
| BioArctic AB (publ) (BIOA-B) | $974.50 Million | 9.08% | 0.21x | $2.57 Billion |
About AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acous… Read more